Market Overview

CEL-SCI Says Interim Review of Ongoing Phase 3 Trial Showed No safety Concerns

Related CVM
CEL-SCI Quarterly Patient Enrollment In Its Head And Neck Cancer Phase III Trial Increases Eight Fold Over Same Prior Year Period
CEL-SCI Enrolls 22 Patients During October In Its Phase III Immunotherapy Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) announced today that an interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine (Leukocyte Interleukin, Injection) investigational immunotherapy by an Independent Data Monitoring Committee (IDMC) raised no safety concerns. The IDMC also indicated that no safety signals were found that would call into question the benefit/risk of continuing the study. CEL-SCI considers the results of the IDMC review to be important since studies have shown that up to 30% of Phase III trials fail due to safety considerations and the IDMC's safety findings from this interim review were similar to those reported by investigators during CEL-SCI's Phase I-II trials. Ultimately, the decision as to whether a drug is safe is made by the FDA based on an assessment of all of the data from a trial.

Posted-In: News FDA

 

Related Articles (CVM)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional